A Phase 2 interventional study of LV232 40mg and LV232 60mg in MDD, sponsored by Vigonvita Life Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Vigonvita Life Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.
This study adopts a multicenter, randomized, double-blind, placebo- and active-controlled parallel-group clinical trial design, aiming to evaluate the efficacy and safety of LV232 capsules ( 40 mg, and 60 mg, once daily) in patients with major depressive disorder (MDD).
The trial plans to enroll 400 subjects, stratified by first episode or recurrence of the disease. Participants will be randomized in a 1:1:1:1 ratio into five groups: LV232 capsules 40 mg, 60 mg, placebo, and active control, with 100 subjects in each group. The treatment will be administered once daily for 8 consecutive weeks.
Vigonvita Life Sciences is the lead sponsor of 39 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsule, 40 mg or 60 mg, administered orally once daily for 8 consecutive weeks
Drug: LV232 40mg · Drug: LV232 60mg
Tablet, 10 mg , administered orally once daily for 8 consecutive weeks
Drug: Escitalopram
Capsule/Tablet, administered orally once daily for 8 consecutive weeks
Drug: Placebo
LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
Also known as: Low-dose group
LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
Also known as: High-dose group
LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
Also known as: Active Comparator
LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet
Also known as: Placebo Comparator,
Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)
The MADRS is a clinician-rated scale used to evaluate depressive symptoms over the preceding week. Participants are assessed on 10 items-including feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest-each scored on a 7-point scale (0 = no symptoms, 6 = maximum severity). The total score ranges from 0 to 60, with higher scores indicating greater depression severity. A negative change in score signifies improvement. Change = (Week 8 post-dose score - baseline week 0 score). at the end of treatment (week 8)
Time frame: Baseline and week 8
Change from baseline in Hamilton Depression Scale (HAMD-17) at week 8
The HAMD-17 is a 17-item, clinician-rated scale that assesses depressive symptoms. The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher HAMD-17 scores indicate more severe depression. Change = (Week 8 post-dose score - baseline week 0 score).
Time frame: Baseline, week 8
Change from baseline in Hamilton Anxiety Inventory (HAMA) scores at week 8
The HAMA is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAMA total score is the sum of the 14 items and the score ranges from 0 to 56, 0 is considered the best outcome. Change = (Week 8 post-dose score - baseline week 0 score).
Time frame: Baseline, week 8
Change from baseline in CGI-S score at week 8
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment. The CGI-S will provide an overall clinician-determined summary measure that takes into account all available information including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. Change = (Week 8 post-dose score - baseline week 0 score).
Time frame: Baseline and week 8
CGI-I score at week 8
The CGI-I assesses the subject's improvement (or worsening). The rater is required to assess the subject's condition relative to baseline\* on a 7-point scale. In all cases, the assessment should be made independent of whether the rater believes the improvement is study medication-related or not.
Time frame: Baseline, week 8
Change from baseline in PHQ-9 score at week 8
The PHQ-9 scale consists of 9 items, each corresponding to a core symptom of depression, including depressed mood, loss of interest, sleep disturbances, fatigue, changes in appetite, feelings of guilt, difficulty concentrating, psychomotor retardation or agitation, and suicidal thoughts. Patients are required to rate each item based on their experiences over the past two weeks, with scores ranging from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.
Time frame: Baseline, week 8
Change from baseline in PDQ-D5 score at week 8
The PDQ-D5 is used to assess cognitive symptoms, describing potential issues that participants may experience with memory, attention, or concentration. Based on their experiences over the past 7 days, participants select the most appropriate option for each item. The scale consists of 5 items, each with 5 response options (scored 0-4). The total score ranges from 0 to 20, with higher scores indicating more severe cognitive symptoms.
Time frame: Baseline, week 8
Change from baseline in DSST score at week 8
The DSST (Digit Symbol Substitution Test) is used to assess processing speed, attention, and visuomotor coordination. Based on a digit-symbol coding key where each number 1-9 corresponds to a unique symbol, participants match as many symbols to their corresponding numbers as possible within 90 seconds. Higher scores indicate better cognitive function.
Time frame: Baseline and week 8
Change from baseline in SHAPPS score at week 8
The SHAPS (Snaith-Hamilton Pleasure Scale) consists of 14 items assessing hedonic responses to common daily life situations, including but not limited to eating, hobbies/recreational activities, and other typical sources of pleasure.
Time frame: Baseline and week 8
SMQD score at week 8
The Somatic Symptoms Questionnaire for Mental Disorders (SQMD) is a self-rated assessment tool primarily designed to evaluate the severity of common somatic symptoms associated with psychiatric disorders-including depressive disorders, bipolar disorders, anxiety disorders, and somatic symptom disorders-over the past week.
Time frame: Baseline and week 8
MARS score at week 8
The Medication Satisfaction Rating Scale (MSRS) is a self-rated questionnaire designed to assess patients' satisfaction levels with their current medication regimen.
Time frame: week 8
Change from baseline in ASEX score at week 8
The Arizona Sexual Experience Scale (ASEX) is a 5-item rating scale where each item is scored from 1 (hyperfunction) to 6 (hypofunction), with gender-specific versions (male and female) tailored to the assessed individual.
Time frame: Baseline and week 8
Change from baseline in C-SSRS score at week 8
The Columbia Suicide Severity Rating Scale (C-SSRS) is a standardized clinical instrument specifically designed for the assessment of suicide risk.
Time frame: Baseline and week 8
Incidence of adverse events (AE)
The AEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.
Time frame: Throughout the study period
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LV232